The Netherlands: Sun v. Novartis (zoledronic acid), District Court of The Hague, ECLI:NL:RBDHA:2015:14337, 25 November 2015
Kluwer Patent Blog
August 29, 2016
Please refer to this post as:, ‘The Netherlands: Sun v. Novartis (zoledronic acid), District Court of The Hague, ECLI:NL:RBDHA:2015:14337, 25 November 2015’, Kluwer Patent Blog, August 29 2016, http://patentblog.kluweriplaw.com/2016/08/29/the-netherlands-sun-v-novartis-zoledronic-acid-district-court-of-the-hague-eclinlrbdha201514337-25-november-2015/
Therapeutic effect of a 2-10mg once yearly dosage regimen is made plausible by an example showing clinical effect of dosage regimens of 0.25, 0.50 and 1mg per three months, 2.0 mg every six months and 4.0 mg once a year. For the purpose of the problem-solution approach, two documents describing a treatment of diseases which have the same underlying cause (bone resorption) do not necessarily have the same purpose. Indirect infringement of a Swiss-type claim is not possible.